(2,5-Dioxopyrrolidin-1-yl) 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2,5-Dioxopyrrolidin-1-yl) 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanoate
• 英文别名: (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanoate
• 化学式: C₁₃H₂₂N₂O₇
• 分子量: 318.32
• InChiKey: OZVLFDJZKAVYLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  22
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES<br/>[FR] ANTICORPS FONCTIONNALISÉS BILATÉRALEMENT PAR CYCLOADDITION
  申请人：SYNAFFIX BV

  公开号：WO2021144314A1

  公开（公告）日：2021-07-22

  The present invention provides antibody-payload conjugates having a payload-to-antibody ratio of 1. The antibody-payload conjugate is according to structure (1): formula (1), wherein: - a, b, c and d are each independently 0 or 1; - e is an integer in the range of 0 - 10; - L1, L2 and L3 are linkers; - D is a payload; - BM is a branching moiety; - Su is a monosaccharide; - G is a monosaccharide moiety; - GlcNAc is an N-acetylglucosamine moiety; - Fuc is a fucose moiety; - Z are connecting groups. The invention further provides a method for preparing the antibody-payload conjugate according to the invention, an intermediate compound in that preparation method, and medical uses of the antibody-payload conjugate according to the invention.

  本发明提供了一种抗体-有效载荷偶联物，其有效载荷与抗体的比例为1。所述抗体-有效载荷偶联物如结构(1)所示：公式(1)，其中：- a、b、c和d每个独立地为0或1；- e是0至10之间的整数；- L1、L2和L3是连接臂；- D是有效载荷；- BM是分支基团；- Su是单糖；- G是单糖基团；- GlcNAc是N-乙酰葡萄糖胺基团；- Fuc是岩藻糖基团；- Z是连接基团。本发明还提供了根据本发明制备抗体-有效载荷偶联物的方法、该制备方法中的中间化合物，以及根据本发明的抗体-有效载荷偶联物的医疗用途。
• [EN] DENDRITIC CORE COMPOUNDS<br/>[FR] COMPOSÉS À CŒUR DENDRITIQUE
  申请人：CALLAGHAN INNOVATION RES LTD

  公开号：WO2014084743A1

  公开（公告）日：2014-06-05

  The invention relates to compounds that are useful for the preparation of dendrimer compounds, the use of these compounds for preparing dendrimers and processes for preparing the compounds.

  本发明涉及用于制备树枝状化合物有用的化合物，以及使用这些化合物来制备树枝状化合物的方法以及制备这些化合物的过程。
• Anti-CD276 antibodies (B7H3)
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH

  公开号：US10604582B2

  公开（公告）日：2020-03-31

  Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.

  本研究公开了能与 CD276 特异性结合并在免疫学上识别 CD276 的多肽和蛋白质。还公开了嵌合抗原受体（CAR）、抗 CD276 结合分子、核酸、重组表达载体、宿主细胞、细胞群、药物组合物以及与多肽和蛋白质有关的共轭物。还公开了检测哺乳动物体内是否存在(a)癌症或(b)肿瘤血管的方法，以及(a)治疗或预防哺乳动物体内癌症或(b)减少肿瘤血管的方法。
• ANTI-CD276 ANTIBODIES (B7H3)
  申请人：The U.S.A. as represented by the Secretary, Department of Health and Human Services

  公开号：EP3193933B1

  公开（公告）日：2021-04-28
• [EN] ANTI-CD276 ANTIBODIES (B7H3)<br/>[FR] ANTICORPS ANTI-CD276 (B7H3)
  申请人：US HEALTH

  公开号：WO2016044383A1

  公开（公告）日：2016-03-24

  Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.